![conference banner](/images/conference-banner.jpeg)
Abstract
MicroRNAs (miRNAs) are short (∼22 nucleotides), highly conserved non-coding RNA molecules that bind to sequences in the 3 untranslated region (3 UTR) of genes with full or partial complementarity, leading to their degradation and/or translational inhibition. Dysregulation of miRNA expression is associated with several human cancers and accumulation of these molecules differs significantly between normal and neoplastic cells. Several miRNAs act as oncogenes by inhibiting tumor suppressors and are over-expressed in cancers, whereas others function as tumor suppressors by inhibiting oncogenes, and are down-regulated or lost in cancers. Moreover, many miRNAs regulate multiple genes associated with one or more cancer pathways, acting as “master switches”, making them ideal targets for the treatment of this disease. Modified RNA molecules that resist nuclease degradation and mimic miRNAs or inactivate them through binding with strong affinity inhibit cancer growth and progression in animal models. The success of repressing neoplastic growth by targeting miRNAs in vivo provides an exciting prospect of using these molecules in cancer therapeutics. Here we review the current data on the involvement of miRNAs in cancer, their mechanism of action and role as “master switches”. In this review, we also discuss the prospect of targeting these “master switches” in therapeutic intervention of this disease, highlighting miRNA-based successful cancer therapy in preclinical animal models and its challenges. We finally conclude by discussing the potential of using dietary agents to modulate expression of miRNAs in cancer.
Keywords: microRNA, miRNA, cancer treatment, oncomir, antimiR, antagomir, miRNA therapy
Current Cancer Therapy Reviews
Title: MicroRNAs in Cancer Therapy: From Bench to Bedside
Volume: 6 Issue: 2
Author(s): Srikumar Sengupta and Anupam Bishayee
Affiliation:
Keywords: microRNA, miRNA, cancer treatment, oncomir, antimiR, antagomir, miRNA therapy
Abstract: MicroRNAs (miRNAs) are short (∼22 nucleotides), highly conserved non-coding RNA molecules that bind to sequences in the 3 untranslated region (3 UTR) of genes with full or partial complementarity, leading to their degradation and/or translational inhibition. Dysregulation of miRNA expression is associated with several human cancers and accumulation of these molecules differs significantly between normal and neoplastic cells. Several miRNAs act as oncogenes by inhibiting tumor suppressors and are over-expressed in cancers, whereas others function as tumor suppressors by inhibiting oncogenes, and are down-regulated or lost in cancers. Moreover, many miRNAs regulate multiple genes associated with one or more cancer pathways, acting as “master switches”, making them ideal targets for the treatment of this disease. Modified RNA molecules that resist nuclease degradation and mimic miRNAs or inactivate them through binding with strong affinity inhibit cancer growth and progression in animal models. The success of repressing neoplastic growth by targeting miRNAs in vivo provides an exciting prospect of using these molecules in cancer therapeutics. Here we review the current data on the involvement of miRNAs in cancer, their mechanism of action and role as “master switches”. In this review, we also discuss the prospect of targeting these “master switches” in therapeutic intervention of this disease, highlighting miRNA-based successful cancer therapy in preclinical animal models and its challenges. We finally conclude by discussing the potential of using dietary agents to modulate expression of miRNAs in cancer.
Export Options
About this article
Cite this article as:
Sengupta Srikumar and Bishayee Anupam, MicroRNAs in Cancer Therapy: From Bench to Bedside, Current Cancer Therapy Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339410791202501
DOI https://dx.doi.org/10.2174/157339410791202501 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore the cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the ...read more
Current progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Oxidative Stress in Polycystic Ovary Syndrome
Current Women`s Health Reviews Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations
Current Clinical Pharmacology Mediterranean Diet and Longevity
Current Nutrition & Food Science Variations and Abnormalities of Major Thoracic Vascular Structures
Current Medical Imaging Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Current Medicinal Chemistry Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Diabetes and the Impairment of Reproductive Function: Possible Role of Mitochondria and Reactive Oxygen Species
Current Diabetes Reviews Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Frequency Domain Mapping of Atrial Fibrillation - Methodology, Experimental Data and Clinical Implications
Current Cardiology Reviews The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology The Impact of IL-17 in Atherosclerosis
Current Medicinal Chemistry Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases
Current Drug Targets Variation of Antioxidant Capacity in Different Layers of Onion (Allium cepa L.) At Two Different Stages of Maturation
Current Nutrition & Food Science Endothelial Cell Regulation of Cardiac Metabolism Following Diabetes
Cardiovascular & Hematological Disorders-Drug Targets Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease
Current Medicinal Chemistry N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets